First messenger RNA influenza vaccine outperforms standard-dose vaccination
1. mFlusiva is the first messenger RNA influenza vaccine approved in the United States, with the FLUENT phase 3 trial ...
Tag: mFlusiva
2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome
mFlusiva outperforms standard-dose flu vaccine in adults 50 and older The U.S. Food and Drug Administration (FDA) approved mFlusiva (mRNA-1010) ...
mFlusiva becomes the first mRNA influenza vaccine approved by the FDA
1. The FLUENT trial demonstrated 26.6% relative vaccine efficacy over a standard-dose comparator in adults 50 and older, clearing the ...
FDA Advisory Committee Votes Unanimously to Recommend Moderna’s mRNA Flu Vaccine
1. The FDA's top vaccine advisory committee voted 9-0 on June 18, 2026 to recommend Moderna's mRNA influenza vaccine mFlusiva ...
